July 28, 2017 / 11:40 AM / 2 years ago

BRIEF-Agile Therapeutics reports second quarter 2017 financial results

July 28 (Reuters) - Agile Therapeutics Inc

* Q2 loss per share $0.26

* Q2 earnings per share view $-0.28 — Thomson Reuters I/B/E/S

* Agile Therapeutics Inc - FDA assigns Prescription Drug User Fee Act (PDUFA) goal date of December 26, 2017

* Agile Therapeutics Inc - cash expected to fund operations into Q2 2018

* Agile Therapeutics - as of June 30, co had $33.9 million of cash and cash equivalents compared to $48.8 million of cash and cash equivalents as of December 31, 2016 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below